Archive | June, 2016

RESI Boston 2016: Come to the Hub of Life Sciences to Meet 300+ Investors

30 Jun

By Dennis Ford, Founder & CEO, LSN


The first Redefining Early Stage Investments (RESI) Conference took place on September 16, 2013, and three years later, following highly successful events in San Francisco, Houston and Toronto, RESI will return to Boston for the 10th RESI Conference. Life Science Nation will be hosting the RESI Boston conference in collaboration with Johnson & Johnson Innovation, JLABS on September 13th, 2016.


RESI Boston is a venue for entrepreneurs to meet with 10 categories of investors that LSN tracks including Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. Through the RESI Partnering, fundraising executives can have up to 16 scheduled meetings as well as many more ad-hoc meetings with diverse life science investors who fit their company’s technology sector, indication and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.


MaRS HealthKick Innovation Challenge – Winners Announced

30 Jun

By Nono Hu, Director of Marketing, LSN

Last week at RESI on MaRS, the MaRS HealthKick Innovation Challenge showcased 30 companies from the digital health, biotech, medical device and diagnostics sectors.  These companies were screened and selected from over a hundred applicants; all were very strong competitors, but only one winner could emerge from the all-day exhibition-style contest.  Here are the top 4 entrants, with a tie for third place!

First Place: Perimeter Medical Imaging (Toronto, Canada)

Complimentary tickets to 3 RESI Conference Series events (2 tickets per event) and a GoPro Camera sponsored by MedMarc


Perimeter Medical Imaging develops, patents, and commercializes advanced surgical imaging tools that allow surgeons, radiologists and pathologists to better assess microscopic tissue structures during surgical procedures. Perimeter’s Optical Tissue Imaging System (OTIS™) is the only solution that provides clinicians with an ultra-high resolution image of the entire surface of an excised tissue specimen, providing accurate information in real time, and enabling better surgical decisions and outcomes.


Michael Quigley, VP of Market Research, Life Science Nation Paul Weber, President and CEO, Perimeter Medical Imaging Lynn Carney, Manager, Marketing Dept, Medmarc Insurance Group

Second Place: BresoTec Inc. (Toronto, Canada)

Complimentary tickets to 2 RESI Conference Series events (2 tickets per event)


BresoTec Inc., a Canadian company based in Toronto, Ontario, develops, manufactures and sells products for the diagnosis and treatment of sleep disorders. BresoTec was founded by UHN (University Health Network) and MaRS Innovation.

BresoTec’s first product, BresoDx®, is an innovative device using proprietary acoustic and movement recording technology as an aid in the diagnosis of sleep apnea.

BresoDx® is a cordless, battery operated device that patients can use at home, in their own bed. The accuracy of BresoDx® versus the PSG standard has been tested and validated in several clinical trials led by Drs. Hisham Alshaer and Douglas Bradley of the University Health Network. Such accuracy in a simple, cordless device establishes BresoDx® as an accurate, easy-to-use and cost-effective home sleep test for physicians, patients and health care providers as an aid in the diagnosis of sleep apnea.


Julie Brogren, COO & VP of Global Sales and Marketing, Bresotec Inc. Michael Quigley, VP of Market Research, Life Science Nation Caren Cao, International Business Liaison, Bresotec Inc.


Third Place (Tie): QoC Health (Toronto, Canada)

Complimentary tickets to 1 RESI Conference Series event (2 tickets)


QoC Health is a Certified B Corp enabling patient centered care with mobile solutions, new service delivery models, and cloud computing. QoC Health’s Cloud Connect platform is a healthcare API (or digital spine) on which health tools are added, including post-surgery discharge monitoring, wound care, transitions in care, and decision aids.

QoC Health’s tools are co-designed with patients and clinicians to maximize user experiences. With best-in-class security and privacy, the company’s solutions can interact on a two-way basis with electronic medical records and personal health records to maximize information sharing. The solutions improve patient outcomes and reduce costs for healthcare providers.


Raymond Shih, President & Co-Founder, QoC Health Michael Quigley, VP of Market Research, Life Science Nation


Third Place (Tie): Woven Orthopedic Technologies (Manchester, CT)

Complimentary tickets to 1 RESI Conference Series event (2 tickets)


Woven Orthopedic Technologies is a medical device business that designs and develops orthopedic technologies to treat the rapidly aging global population affected by orthopedic conditions. Their premier technology addresses the #1 problem with the #1 technology used in orthopedics today by enhancing screw fixation in patients who receive treatment for fractures.

Today, the company operates at the core of the intersection between science, technology, and medicine by leveraging advances in smart engineered bio-textiles to design technologies that help provide better care for less cost, to more people around the world.


Michael Quigley, VP of Market Research, Life Science Nation Ilana Odess, CEO, Woven Orthopedic Technologies

Thank you to all who competed in the MaRS HealthKick Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.  If you’d like to be part of the RESI Boston Innovation Challenge, apply now.


LSN Summer Reading Series Chapter 5: “Knowing Who and What You Are, and Where You Fit”

30 Jun

By Lucy Parkinson, Director of Research, LSN

In this latest edition of the summer reading series, we will be explaining the importance of understanding where your opportunity fits within the marketplace. Knowing who you are and how you compare with other companies in the space is crucial in determining the investors to whom you should be reaching out, what you should be highlighting in your marketing materials, and, in some cases, whether you need to “pivot,” or change, your commercialization plan.

Chapter 5 of The Life Science Executive’s Fundraising Manifesto, “Knowing Who and What You Are, and Where You Fit,” discusses how to define yourself and your market, as well as the importance of being able to pivot after receiving feedback and how to identify when it is strategically relevant to do so.

Click here to download/print the PDF.

We hope this text proves to be informative. Join us next week for Chapter 6: “Branding and Messaging”, for some tactical tips on how to build a brand for your company.

Enjoyed the preview? Buy now from or Barnes & Noble


Hot Investor Mandate 1: Private Wealth Fund Targets Preclinical Oncology Therapeutics

30 Jun

A specialist investor funded by private investors and which has operations in Europe and the USA exclusively focuses on investments in early-stage drug development companies targeting cancer therapies. The firm is most interested in companies from late seed stage to Series A. The investment size will vary, and it can range from a few hundred thousand dollars up to a couple of million dollars. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapies within the oncology space, including platform technology. The firm will not invest in medical devices or diagnostics. The firm typically invests in companies with solid preclinical proof-of-concept (late preclinical stage/pre-IND), and will fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa). Historically, the firm was active in companies targeting immunotherapy and tumor cell metabolism within the oncology field, but does not restrict future investments to these strategies within oncology as the firm is open to new targets and approaches within the field.

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm looks to be a lead investor and typically prefers a board seat upon investment. As a strategic investor, the firm will support portfolio companies with partnership management services, including filling management teams with experts in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 2: Healthcare System Corporate VC Seeks Healthcare IT & Services with B2B Focus

30 Jun

The corporate venture capital arm of an integrated healthcare system is making investments out of a $150 million dollar fund. The firm can invest as little as $5 million but tends to allocate $7-$10 million initially, and $10-$15 million over the lifetime of an investment. The firm only invests in preferred equity rounds, and is comfortable leading life sciences deals, particularly in healthcare IT. The firm only invests in US-based and incorporated companies. The group is a strategic investor capable of forging relationships with the health system, but is also financially motivated. The firm is involved in approximately 4-5 new investments each year.

The firm is primarily interested in healthcare IT and healthcare services companies with a B2B focus. Physician-facing health IT technologies are also of interest, but given the inherent difficulties with adoption of such technologies, would need significant traction/users to be considered. Diagnostics, medical devices and drug delivery companies will be evaluated secondarily, pending and necessary FDA approval has been received. Companies that are able to benefit the healthcare system’s members are of particular interest. The firm is indication agnostic, however, and is not interested in investing into companies working with novel compounds or therapeutics. The firm is looking for mid to later-stage companies for investment.

The firm looks to invest in companies that have already received institutional funding from highly qualified investors where the investor syndicate has majority stake in the company. The firm will consider companies that are both pre and post-revenue, but is primarily interested in companies with early (single digit millions) commercial traction.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 3: VC Fund Invests in Medtech & Diagnostics in Midwest and Northeast US and Canada

30 Jun

An early-stage venture capital firm based in Toronto, Canada is making medtech investments out of its third fund. The firm generally looks to make investments in companies ranging from $1 – $5 million initially and up to $10 million over the life of the investment. The firm is focused on Canadian companies, but will work with companies in the Northeastern and Midwestern U.S. as well. The firm aims to make approximately 2-3 new investments per year.

Within the life science space, the firm is looking for medical device and diagnostics companies that have a clear path to FDA approval, and will look at any devices/diagnostics, pre-FDA approval including 510(k) and PMA pathways. In addition to medtech, the firm is also interested in health IT with the focus being on B2B software-centric companies. The firm is looking for companies that have managed to demonstrate market interest in their product prior to investment.

The firm looks to be a very active investor in chosen companies and always pursues a board seat. The firm looks for strong experienced management teams and looks to bring their own entrepreneurial experience to aid in the growth and expansion of companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 4: China Joint Venture Seeks Drug and Device Deals in USA

30 Jun

A Shanghai-based private equity fund formed through a partnership between two Chinese healthcare firms is focusing on pharmaceuticals, medical device & diagnostics, and medical services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is currently seeking opportunities from China and the U.S.

The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; biotech products in Biosimilar, Vaccines, blood product, etc.; and Traditional Chinese Medicine (TCM). Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barriers, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. In addition, the firm is seeking R&D services that support cell therapy, stem cell, and new therapies. For first-in-class products, the firm prefers products in Phase 2 trials or later. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.

The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers company with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has strong network in China and can offer assistance in distribution and registration.

If you are interested in more information about this investor and other investors tracked by LSN, please email